Education
About Us
Working with TipRanks
Follow Us
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
RARE Stock Chart & Stats
$32.54
-$0.60(-1.35%)
At close: 4:00 PM EST
$32.54
-$0.60(-1.35%)
Day’s Range― - ―
52-Week Range$25.81 - $50.00
Previous CloseN/A
Volume75.38K
Average Volume (3M)1.38M
Market Cap
$3.19B
Enterprise Value$3.44B
Total Cash (Recent Filing)$425.25M
Total Debt (Recent Filing)$863.11M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Feb 12, 2026EPS Estimate
-1.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.81
Shares Outstanding96,477,570
10 Day Avg. Volume1,487,187
30 Day Avg. Volume1,376,787
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)14.92
Price to Sales (P/S)6.80
P/FCF Ratio-9.03
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue5.45
Enterprise Value/Gross Profit6.43
Enterprise Value/Ebitda-7.11
Forecast
1Y Price Target
$77.08Price Target Upside136.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Funding StrategyRARE strengthened liquidity with $400M non-dilutive financing from OMERS, deferring payments until 2028 to support launch readiness and maintain its path to profitability in 2027.
Market OpportunityThe OI market opportunity is estimated to be 50-100% larger than XLH, with pricing expected to mirror Crysvita and early uptake likely in severe Type 3/4 patients.
Therapeutic AdvancesThe results from the Phase 3 GlucoGene study with DTX401 showed greater reductions in daily cornstarch intake and maintained low levels of hypoglycemia, indicating strong therapeutic benefits.
Bears Say
Earnings ReportRARE reported a 3Q25 GAAP EPS of $(1.81), which compared unfavorably to consensus estimates.
Revenue PerformanceThe 3Q25 total revenue of $160M missed versus consensus estimates.
Stock Price ReactionThe stock was down 17% after hours in response to the news.
Ultragenyx Pharmaceutical News
RARE FAQ
What was Ultragenyx Pharmaceutical’s price range in the past 12 months?
Ultragenyx Pharmaceutical lowest stock price was $25.81 and its highest was $50.00 in the past 12 months.
What is Ultragenyx Pharmaceutical’s market cap?
Ultragenyx Pharmaceutical’s market cap is $3.19B.
When is Ultragenyx Pharmaceutical’s upcoming earnings report date?
Ultragenyx Pharmaceutical’s upcoming earnings report date is Feb 12, 2026 which is in 85 days.
How were Ultragenyx Pharmaceutical’s earnings last quarter?
Ultragenyx Pharmaceutical released its earnings results on Nov 04, 2025. The company reported -$1.81 earnings per share for the quarter, missing the consensus estimate of -$1.234 by -$0.576.
Is Ultragenyx Pharmaceutical overvalued?
According to Wall Street analysts Ultragenyx Pharmaceutical’s price is currently Undervalued.
Does Ultragenyx Pharmaceutical pay dividends?
Ultragenyx Pharmaceutical does not currently pay dividends.
What is Ultragenyx Pharmaceutical’s EPS estimate?
Ultragenyx Pharmaceutical’s EPS estimate is -1.16.
How many shares outstanding does Ultragenyx Pharmaceutical have?
Ultragenyx Pharmaceutical has 96,477,570 shares outstanding.
What happened to Ultragenyx Pharmaceutical’s price movement after its last earnings report?
Ultragenyx Pharmaceutical reported an EPS of -$1.81 in its last earnings report, missing expectations of -$1.234. Following the earnings report the stock price went down -1.818%.
Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical?
Currently, no hedge funds are holding shares in RARE
Ultragenyx Pharmaceutical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$77.08 (136.88% Upside)
$77.08 (136.88% Upside)
Blogger Sentiment
Bullish
RARE Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $252.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.28%
12-Months-Change
Fundamentals
Return on Equity
-325.76%
Trailing 12-Months
Asset Growth
-22.62%
Trailing 12-Months
Company Description
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing innovative therapies for rare and ultra-rare genetic diseases. Established in 2010, the company operates primarily in the biotechnology sector and specializes in the research, development, and commercialization of treatments that address unmet medical needs for patients suffering from these conditions. Ultragenyx's core products include enzyme replacement therapies and other novel therapeutics targeting specific genetic disorders, with a portfolio that includes therapies like Crysvita and Mepsevii.
RARE Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook due to strong financial positioning, consistent revenue growth, and promising pipeline advancements, despite challenges such as net losses and regulatory hurdles.View all RARE earnings summariesRARE Stock 12 Month Forecast
Average Price Target
$77.08
▲(136.88% Upside)
Technical Analysis
PTC Therapeutics
―
Crispr Therapeutics AG
―
Zai Lab
―
Springworks Therapeutics
―
Arcellx Inc
―
Ownership Overview
4.00% Insiders
29.65% Mutual Funds
10.87% Other Institutional Investors
40.81% Public Companies and Individual Investors